EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Idiopathic Anaphylaxis

Moshe Ben-Shoshan, Akin Cem, Victoria E Cook, Roy Khalaf, George Freigeh

The Journal of Allergy and Clinical Immunology: In Practice · 2025

DOI: 10.1016/j.jaip.2025.08.019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Moshe Ben-Shoshan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology & Dermatology, Department of Pediatrics, Montreal Children's Hospital, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Anaphylaxis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic anaphylaxis (IA) refers to recurrent, life-threatening hypersensitivity reactions without identifiable triggers, representing a diagnostic and therapeutic challenge. We describe a 17-year-old girl presenting with recurrent episodes of flushing, pruritus, and respiratory symptoms, without consistent allergen exposure or cofactor involvement. Evaluation revealed elevated acute tryptase levels with a normal baseline, negative skin testing results, and negative galactose-α-1,3-galactose (α-gal) and KIT mutation analysis. The patient improved on daily cetirizine with no further reactions. IA remains a diagnosis of exclusion, requiring careful consideration of IgE-mediated allergies, cofactor-dependent anaphylaxis, clonal mast cell disorders, and systemic mimics such as neuroendocrine tumors or vasovagal syncope. We summarize current evidence on IA pathogenesis, epidemiology, differential diagnosis, and management. Although antihistamines and corticosteroids are commonly used prophylactically, emerging data suggest that anti-IgE therapy with omalizumab may offer benefit in refractory cases. Diagnostic workup should include serum tryptase measurement, trigger identification, and consideration of underlying mast cell disorders. Future research is needed to clarify the natural history, standardize diagnostic pathways, and evaluate long-term treatment strategies for this heterogeneous condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnaphylaxisAdolescentFemaleHumansAnti-Allergic AgentsCetirizineDiagnosis, DifferentialImmunoglobulin EOmalizumabTryptases

Stichwörter der Autor:innen

AnaphylaxisIdiopathic anaphylaxisMast cellMast cell activation syndromeTryptase

Substanzen

Anti-Allergic AgentsCetirizineImmunoglobulin EOmalizumabTryptases

Autor:innen und Institutionen

  • Division of Allergy, Immunology & Dermatology, Department of Pediatrics, Montreal Children's Hospital, Montreal, Quebec, Canada.
  • Division of Allergy and Immunology, Department of Medicine, University of Michigan, Ann Arbor, Mich.
  • Division of Allergy, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
  • Faculty of Medicine & Health Sciences, McGill University, Montreal, Quebec, Canada. Electronic address: roy.khalaf@mail.mcgill.ca.

Zitieren

APA

Ben-Shoshan, M., Cem, A., Cook, V. E., Khalaf, R., & Freigeh, G. (2025). Idiopathic Anaphylaxis. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2025.08.019

Vancouver

Ben-Shoshan M, Cem A, Cook VE, Khalaf R, Freigeh G. Idiopathic Anaphylaxis. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2025.08.019

BibTeX
@article{BenShoshan2025,
  author = {Ben-Shoshan, Moshe and Cem, Akin and Cook, Victoria E and Khalaf, Roy and Freigeh, George},
  title = {Idiopathic Anaphylaxis},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2025},
  doi = {10.1016/j.jaip.2025.08.019}
}
Kostenlos starten →